openPR Logo
Press release

Personalised tumor vaccines keep cancer in check

08-21-2017 02:12 PM CET | Health & Medicine

Press release from: SMi Group

Throughout the last decade, novel cancer therapeutics has seen tremendous developments, through targeting tumor cell-intrinsic pathways, as well as targeting tumor cell-extrinsic factors such as growth factors.

Notable clinical success of checkpoint inhibitors as well as adoptively transferred genetically engineered T cells further demonstrates the critical role of T-cells in cancer control and rejection. However, many patients still do not respond to checkpoint inhibitor therapies. This creates the need for effective means of expanding the T-cells in patients using cancer vaccines, which will be further explored by MSD, Exicure, Genentech and INSERM.

There has been substantial progress made in these fields and It's time to connect these fields to enable the linking of genetic alterations with the type of immune response. SMi's 6th annual Cancer Vaccines conference will host high level cancer geneticists, cancer biologists, experts in cancer antigen, tumor immunologists and vaccinologists, to discuss the immunological basis for therapeutic cancer vaccines and how the current understanding of cancer genomics, antigens and T-cell biology might enable development of next-generation novel therapies for patients with cancer.

With the increasing use of various immunotherapy strategies in the clinic, it is essential for immunomonitoring techniques to be conducted to follow the response of patients to therapy. Such investigations will enable the discovery of neoantigens that may contribute to the efficacy of treatment. The potential cellular players, the use of screening techniques to monitor effects of treatment and an account of an immunotherapy trial will illustrate what is possible in clinical practice.

Running alongside the conference will an exclusive pre-conference workshop held on Tuesday 26th September 2017.

The Biomarkers of immune response workshop is aimed at both clinical and research investigators to give insights into how to develop tools for both developing new therapeutic strategies and how to monitor responses to treatment. This will enable you to design clinical trials and to set up laboratory investigations to evaluate response to immunotherapy.

Workshop hosts:

Rose-Ann Padua, Research Director, INSERM
Antoine Toubert, Head, Alloimmunity, Autoimmunity, Transplantation, INSERM
Eric Tartour, Head, Laboratory of Clinical Immunology, Hopital Europeen George Pompidou
Sharam Kordasti, Senior Lecturer, Kings College London
Zwi Berneman, Professor of Haematology, University of Antwerp

Cancer Vaccines 2017 is proudly sponsored by Northwest Biotherapeutics

6th annual Cancer Vaccines
27th – 28th September 2017
London, UK
www.cancervaccinesevent.com/OPENPR
Contact e-mail: kwilliams@smi-online.co.uk
Contact tel: +44 (0) 207 827 6012
#smicancervac

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Kyra Williams
kwilliams@smi-online.co.uk
SMi Group
1 Westminster Bridge Road
London
SE1 7XW

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Personalised tumor vaccines keep cancer in check here

News-ID: 677523 • Views: 646

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases